BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/9/2022 7:17:55 AM | Browse: 171 | Download: 470
 |
Received |
|
2021-12-11 15:20 |
|
Peer-Review Started |
|
2021-12-11 15:22 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-02-08 00:35 |
|
Revised |
|
2022-03-08 13:55 |
|
Second Decision |
|
2022-04-01 02:17 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-04-04 03:31 |
|
Articles in Press |
|
2022-04-04 03:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-24 07:42 |
|
Publish the Manuscript Online |
|
2022-06-09 07:17 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Case Report |
| Article Title |
Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nobumasa Hojo, Makoto Nagasaki and Yasuha Mihara |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nobumasa Hojo, MD, PhD, Chief Physician, Department of General Medicine, National Hospital Organization Hamada Medical Center, Asai-cho 777-12, Hamada City 697-8511, Shimane, Japan. hojo.nobumasa.qw@mail.hosp.go.jp |
| Key Words |
Key Words: Classical Hodgkin lymphoma; Diffuse large B-cell lymphoma; Gray zone lymphoma; Programmed cell death protein ligand 1; R-CHOP; Case report |
| Core Tip |
The incidence of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (BCLu-DLBCL/cHL), also known as gray zone lymphoma (GZL), is low in Asian populations. A patient presented with right-sided cervical lymph node enlargement. The patient was diagnosed based on the characteristic pathological findings, the immunophenotype [CD20+, PAX5+, OCT2+/BOB1 (focal+), CD30+, CD15-], and the strong positive expression of neoplastic programmed cell death protein ligand 1 in her lymphoma cells. There is no consensus regarding the optimal therapeutic regimen for GZL. The addition of rituximab to the chemotherapy regimen should be considered if the tumor cells are CD20+. The patient was successfully treated with the cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab regimen and has remained in complete remission for 3 years. |
| Publish Date |
2022-06-09 07:17 |
| Citation |
Hojo N, Nagasaki M, Mihara Y. Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report. World J Clin Cases 2022; 10(17): 5708-5716 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i17/5708.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i17.5708 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
